vs
FNB CORP（FNB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
FNB CORP的季度营收约是Orthofix Medical Inc.的1.7倍（$366.0M vs $219.9M），FNB CORP净利率更高（45.9% vs -1.0%，领先46.9%），FNB CORP同比增速更快（13.7% vs 2.0%），FNB CORP自由现金流更多（$99.0M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.1%）
FNB集团是总部位于美国宾夕法尼亚州匹兹堡的多元化金融服务机构，为旗下最大子公司第一国民银行的控股主体，截至2025年12月31日总资产超500亿美元，业务覆盖匹兹堡、巴尔的摩、克利夫兰、华盛顿特区、北卡罗来纳州多座城市及南卡罗来纳州查尔斯顿等核心都会区。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FNB vs OFIX — 直观对比
营收规模更大
FNB
是对方的1.7倍
$219.9M
营收增速更快
FNB
高出11.7%
2.0%
净利率更高
FNB
高出46.9%
-1.0%
自由现金流更多
FNB
多$82.2M
$16.8M
两年增速更快
OFIX
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $366.0M | $219.9M |
| 净利润 | $168.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 45.1% | 0.2% |
| 净利率 | 45.9% | -1.0% |
| 营收同比 | 13.7% | 2.0% |
| 净利润同比 | 52.7% | 92.4% |
| 每股收益（稀释后） | $0.47 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNBOFIX
| Q4 25 | $366.0M | $219.9M | ||
| Q3 25 | $359.0M | $205.6M | ||
| Q2 25 | $348.0M | $203.1M | ||
| Q1 25 | $323.0M | $193.6M | ||
| Q4 24 | $322.0M | $215.7M | ||
| Q3 24 | $323.0M | $196.6M | ||
| Q2 24 | $316.0M | $198.6M | ||
| Q1 24 | $319.0M | $188.6M |
净利润FNBOFIX
| Q4 25 | $168.0M | $-2.2M | ||
| Q3 25 | $150.0M | $-22.8M | ||
| Q2 25 | $130.0M | $-14.1M | ||
| Q1 25 | $117.0M | $-53.1M | ||
| Q4 24 | $110.0M | $-29.1M | ||
| Q3 24 | $110.0M | $-27.4M | ||
| Q2 24 | $123.0M | $-33.4M | ||
| Q1 24 | $122.0M | $-36.0M |
毛利率FNBOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率FNBOFIX
| Q4 25 | 45.1% | 0.2% | ||
| Q3 25 | 52.9% | -8.3% | ||
| Q2 25 | 47.7% | -7.9% | ||
| Q1 25 | 45.8% | -25.2% | ||
| Q4 24 | 31.7% | -5.3% | ||
| Q3 24 | 43.3% | -9.6% | ||
| Q2 24 | 49.7% | -12.5% | ||
| Q1 24 | 48.9% | -15.6% |
净利率FNBOFIX
| Q4 25 | 45.9% | -1.0% | ||
| Q3 25 | 41.8% | -11.1% | ||
| Q2 25 | 37.4% | -6.9% | ||
| Q1 25 | 36.2% | -27.4% | ||
| Q4 24 | 34.2% | -13.5% | ||
| Q3 24 | 34.1% | -13.9% | ||
| Q2 24 | 38.9% | -16.8% | ||
| Q1 24 | 38.2% | -19.1% |
每股收益（稀释后）FNBOFIX
| Q4 25 | $0.47 | $-0.05 | ||
| Q3 25 | $0.41 | $-0.57 | ||
| Q2 25 | $0.36 | $-0.36 | ||
| Q1 25 | $0.32 | $-1.35 | ||
| Q4 24 | $0.31 | $-0.76 | ||
| Q3 24 | $0.30 | $-0.71 | ||
| Q2 24 | $0.34 | $-0.88 | ||
| Q1 24 | $0.32 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $82.0M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $6.8B | $450.0M |
| 总资产 | $50.2B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资FNBOFIX
| Q4 25 | $2.5B | $82.0M | ||
| Q3 25 | $2.4B | $62.9M | ||
| Q2 25 | $2.4B | $65.6M | ||
| Q1 25 | $2.4B | $58.0M | ||
| Q4 24 | $2.4B | $83.2M | ||
| Q3 24 | $2.1B | $30.1M | ||
| Q2 24 | $1.9B | $26.4M | ||
| Q1 24 | $1.5B | $27.0M |
总债务FNBOFIX
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.1B | $157.2M | ||
| Q2 25 | $2.7B | $157.0M | ||
| Q1 25 | $2.5B | $156.9M | ||
| Q4 24 | $3.0B | $157.0M | ||
| Q3 24 | $2.5B | $118.5M | ||
| Q2 24 | $2.0B | $118.0M | ||
| Q1 24 | $2.1B | $118.2M |
股东权益FNBOFIX
| Q4 25 | $6.8B | $450.0M | ||
| Q3 25 | $6.6B | $442.5M | ||
| Q2 25 | $6.5B | $458.3M | ||
| Q1 25 | $6.4B | $458.3M | ||
| Q4 24 | $6.3B | $503.1M | ||
| Q3 24 | $6.2B | $525.9M | ||
| Q2 24 | $6.1B | $546.0M | ||
| Q1 24 | $6.0B | $570.3M |
总资产FNBOFIX
| Q4 25 | $50.2B | $850.6M | ||
| Q3 25 | $49.9B | $832.6M | ||
| Q2 25 | $49.7B | $837.2M | ||
| Q1 25 | $49.0B | $823.1M | ||
| Q4 24 | $48.6B | $893.3M | ||
| Q3 24 | $48.0B | $867.9M | ||
| Q2 24 | $47.7B | $882.0M | ||
| Q1 24 | $45.9B | $906.0M |
负债/权益比FNBOFIX
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.32× | 0.36× | ||
| Q2 25 | 0.41× | 0.34× | ||
| Q1 25 | 0.39× | 0.34× | ||
| Q4 24 | 0.48× | 0.31× | ||
| Q3 24 | 0.40× | 0.23× | ||
| Q2 24 | 0.33× | 0.22× | ||
| Q1 24 | 0.35× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 27.0% | 7.6% |
| 资本支出强度资本支出/营收 | 7.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.76× | — |
| 过去12个月自由现金流最近4个季度 | $376.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FNBOFIX
| Q4 25 | $128.0M | $27.7M | ||
| Q3 25 | $167.0M | $12.4M | ||
| Q2 25 | $123.0M | $11.6M | ||
| Q1 25 | $64.0M | $-18.4M | ||
| Q4 24 | $326.0M | $23.7M | ||
| Q3 24 | $-14.0M | $11.7M | ||
| Q2 24 | $85.0M | $9.0M | ||
| Q1 24 | $245.0M | $-18.6M |
自由现金流FNBOFIX
| Q4 25 | $99.0M | $16.8M | ||
| Q3 25 | $149.0M | $2.5M | ||
| Q2 25 | $85.0M | $4.5M | ||
| Q1 25 | $43.0M | $-25.1M | ||
| Q4 24 | $278.0M | $15.2M | ||
| Q3 24 | $-46.0M | $6.3M | ||
| Q2 24 | $55.0M | $-360.0K | ||
| Q1 24 | $216.0M | $-29.1M |
自由现金流率FNBOFIX
| Q4 25 | 27.0% | 7.6% | ||
| Q3 25 | 41.5% | 1.2% | ||
| Q2 25 | 24.4% | 2.2% | ||
| Q1 25 | 13.3% | -13.0% | ||
| Q4 24 | 86.3% | 7.0% | ||
| Q3 24 | -14.2% | 3.2% | ||
| Q2 24 | 17.4% | -0.2% | ||
| Q1 24 | 67.7% | -15.4% |
资本支出强度FNBOFIX
| Q4 25 | 7.9% | 4.9% | ||
| Q3 25 | 5.0% | 4.8% | ||
| Q2 25 | 10.9% | 3.5% | ||
| Q1 25 | 6.5% | 3.5% | ||
| Q4 24 | 14.9% | 4.0% | ||
| Q3 24 | 9.9% | 2.7% | ||
| Q2 24 | 9.5% | 4.7% | ||
| Q1 24 | 9.1% | 5.6% |
现金转化率FNBOFIX
| Q4 25 | 0.76× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 2.96× | — | ||
| Q3 24 | -0.13× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 2.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNB
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
